ProfileGDS5678 / 1423456_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 81% 80% 79% 81% 81% 79% 80% 80% 81% 84% 82% 83% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3915178
GSM967853U87-EV human glioblastoma xenograft - Control 25.8268981
GSM967854U87-EV human glioblastoma xenograft - Control 35.5948180
GSM967855U87-EV human glioblastoma xenograft - Control 45.6701679
GSM967856U87-EV human glioblastoma xenograft - Control 55.7777181
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5954881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4423579
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.563880
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6090580
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8908981
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2792484
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9906182
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0626983
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.938182